Difference between revisions of "Trabectedin (Yondelis)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000773/WC500045832.pdf Trabecte...")
 
Line 1: Line 1:
 +
Also known as ecteinascidin 743 or ET-743.
 +
 
==General information==
 
==General information==
Class/mechanism: <ref name="insert">[http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000773/WC500045832.pdf Trabectedin (Yondelis) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/trabectedin.pdf Trabectedin (Yondelis) package insert (locally hosted backup)]</ref>
+
Class/mechanism: Binds to the minor groove of DNA, which distorts the DNA helix and its major groove.  This binding interrupts normal cell function and interferes with the expression of several several transcription factors, DNA binding proteins, and DNA repair mechanisms, which interrupts cell cycle and leads to tumor death.<ref name="insert">[http://www.janssen.ca/subcategory_docdownload?id=633 Trabectedin (Yondelis) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/trabectedin.pdf Trabectedin (Yondelis) package insert (locally hosted backup)]</ref>
<br>Route: TBD
+
<br>Route: IV
<br>Extravasation: TBD
+
<br>Extravasation: [[vesicant]]
  
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>.  
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information<ref name="insert"></ref>.  
  
 
==Patient drug information==
 
==Patient drug information==
 +
*[http://www.janssen.ca/subcategory_docdownload?id=634 Trabectedin (Yondelis) patient drug information from manufacturer]<ref>[http://www.janssen.ca/subcategory_docdownload?id=634 Trabectedin (Yondelis) patient drug information from manufacturer]</ref>
 
*[http://www.uptodate.com/contents/trabectedin-patient-drug-information Trabectedin (Yondelis) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/trabectedin-patient-drug-information Trabectedin (Yondelis) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/trabectedin-patient-drug-information Trabectedin (Yondelis) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/trabectedin-patient-drug-information Trabectedin (Yondelis) patient drug information (UpToDate)]</ref>
  
 
==References==
 
==References==
 
<references/>
 
<references/>

Revision as of 00:12, 26 February 2012

Also known as ecteinascidin 743 or ET-743.

General information

Class/mechanism: Binds to the minor groove of DNA, which distorts the DNA helix and its major groove. This binding interrupts normal cell function and interferes with the expression of several several transcription factors, DNA binding proteins, and DNA repair mechanisms, which interrupts cell cycle and leads to tumor death.[1][2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information[1].

Patient drug information

References